These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 28895260)
1. Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy. Wang L; Liu T; Zhou J; You H; Jia J Hepatol Res; 2018 Feb; 48(3):E283-E290. PubMed ID: 28895260 [TBL] [Abstract][Full Text] [Related]
2. Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication. Kang Q; Chen J; Luo H; Tan N; Gao H; Zhang X; Yu M; Liu D; Xi H; An Y; Han Y; Cheng R; Xu X Dis Markers; 2020; 2020():8539804. PubMed ID: 33082884 [TBL] [Abstract][Full Text] [Related]
3. Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China. Jin X; Fu B; Wu ZJ; Zheng XQ; Hu JH; Jin LF; Tang LL Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):384-389. PubMed ID: 32540209 [TBL] [Abstract][Full Text] [Related]
4. Non-Invasive Monitoring of the Impact of Low-Level Viremia on Liver Fibrosis in Treated Chronic Hepatitis B Patients. Xu J; Zhang Y; Zhu L; Tang S; Xu H; Zhang D; Chen H; Zhou J Infect Drug Resist; 2024; 17():2751-2758. PubMed ID: 38974312 [TBL] [Abstract][Full Text] [Related]
5. Association between chitinase-3-like protein 1 and metabolic-associated fatty liver disease in patients with type 2 diabetes mellitus. Zhang F; Han Y; Zheng L; Bao Z; Liu L; Li W Ir J Med Sci; 2024 Aug; 193(4):1843-1853. PubMed ID: 38520612 [TBL] [Abstract][Full Text] [Related]
6. Expression of chitinase-3-like protein 1 in different TCM syndromes and its correlation with liver fibrosis. Li H; Xu X; Yi T; Zheng T; Yan T Ann Palliat Med; 2022 Jan; 11(1):217-224. PubMed ID: 35144413 [TBL] [Abstract][Full Text] [Related]
7. [Diagnostic value of novel hepatic fibrosis markers in assessing cirrhosis in patients with chronic hepatitis C]. Kang Q; Liu JX; Tan N; Chen HY; Pan JL; Han YF; Xu XY Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):56-64. PubMed ID: 36948850 [No Abstract] [Full Text] [Related]
8. Serum CHI3L1 as a diagnostic marker and risk factor for liver fibrosis in HBeAg-negative chronic hepatitis B. Li Y; Li C; Zhang L; Hu W; Luo H; Li J; Qiu S; Zhu S Am J Transl Res; 2022; 14(6):4090-4096. PubMed ID: 35836859 [TBL] [Abstract][Full Text] [Related]
9. [Diagnostic value of serum chitinase-3-like protein 1 in chronic liver disease of significant fibrosis and cirrhosis]. Li H; Yan T; Zhu Z; Bao ZW; Xu TM; Xie J; Zheng SQ; Cui MM; Liu LG Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):337-341. PubMed ID: 29996200 [No Abstract] [Full Text] [Related]
10. Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir. Kong Y; Sun Y; Zhou J; Wu X; Chen Y; Piao H; Lu L; Ding H; Nan Y; Jiang W; Xu Y; Xie W; Li H; Feng B; Shi G; Chen G; Li H; Zheng H; Cheng J; Wang T; Liu H; Lv F; Shao C; Mao Y; Sun J; Chen T; Han T; Han Y; Wang L; Ou X; Zhang H; Jia J; You H J Viral Hepat; 2019 May; 26(5):576-585. PubMed ID: 30624000 [TBL] [Abstract][Full Text] [Related]
11. Declining in liver stiffness cannot indicate fibrosis regression in patients with chronic hepatitis B: A 78-week prospective study. Dong XQ; Wu Z; Li J; Wang GQ; Zhao H; J Gastroenterol Hepatol; 2019 Apr; 34(4):755-763. PubMed ID: 30290019 [TBL] [Abstract][Full Text] [Related]
12. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. Berres ML; Papen S; Pauels K; Schmitz P; Zaldivar MM; Hellerbrand C; Mueller T; Berg T; Weiskirchen R; Trautwein C; Wasmuth HE J Hepatol; 2009 Feb; 50(2):370-6. PubMed ID: 19070929 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Chitinase 3-like 1 (CHI3L1) as a noninvasive biomarker of hepatic fibrosis in patients with Hepatitis B virus-related compensated chronic liver disease. Das A; Kamrul-Hasan A; Kabir MR; Das S; Zaki K; Al Mahtab M J Family Med Prim Care; 2021 Apr; 10(4):1694-1698. PubMed ID: 34123914 [TBL] [Abstract][Full Text] [Related]
14. Analytical and Clinical Evaluation of a Chemiluminescent Immunoassay to Detect Serum Chitinase-3-like Protein 1 in HBV-Related Liver Diseases. Liao Y; Peng S; Huang L; Li Z; Hu J; Xu R; Tang W; Zhuang J Int J Anal Chem; 2024; 2024():6688819. PubMed ID: 38304922 [TBL] [Abstract][Full Text] [Related]
15. Serum CHI3L1 as a Biomarker for Non-invasive Diagnosis of Liver Fibrosis. Bao J; Ouyang Y; Qiao L; He J; Liu F; Wang Y; Miao L; Fu A; Lou Z; Zang Q; Huang W; Huang J; Li Z Discov Med; 2022; 33(168):41-49. PubMed ID: 36274212 [TBL] [Abstract][Full Text] [Related]
16. Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. Mak LY; Wong DK; Seto WK; Ning Q; Cheung KS; Fung J; Lai CL; Yuen MF Hepatol Int; 2019 Mar; 13(2):148-156. PubMed ID: 30671807 [TBL] [Abstract][Full Text] [Related]
18. Diverse correlations between fibrosis-related factors and liver stiffness measurement by transient elastography in chronic hepatitis B. Lin Z; Liang J; Zhu J; Hu C; Gu Y; Lai J; Zheng Y; Gao Z Eur J Gastroenterol Hepatol; 2018 Feb; 30(2):217-225. PubMed ID: 29194232 [TBL] [Abstract][Full Text] [Related]
19. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment. Wu SD; Liu LL; Cheng JL; Liu Y; Cheng LS; Wang SQ; Ma W; Chen LP; Tseng YJ; Wang JY; Shen XZ; Jiang W Clin Exp Med; 2018 Aug; 18(3):433-443. PubMed ID: 29696462 [TBL] [Abstract][Full Text] [Related]
20. The Early On-treatment Stiffness Decline Attributed to the Improved Hepatic Inflammation in Fibrotic Chronic Hepatitis B. Li M; Yao M; Wang L; Liu Y; Ji D; Yang Y; Lu F J Clin Gastroenterol; 2024 Jul; ():. PubMed ID: 38990730 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]